vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Spok Holdings, Inc (SPOK). Click either name above to swap in a different company.
Spok Holdings, Inc is the larger business by last-quarter revenue ($33.9M vs $19.1M, roughly 1.8× NewAmsterdam Pharma Co N.V.). Spok Holdings, Inc runs the higher net margin — 8.7% vs -90.7%, a 99.4% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -0.1%). Spok Holdings, Inc produced more free cash flow last quarter ($10.1M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Spok Holdings, Inc. is a global provider of critical communication solutions primarily serving the healthcare industry. It offers unified clinical communication platforms, secure messaging tools, alerting systems, and on-call scheduling software that help care teams coordinate efficiently, cut response times, and boost patient safety across medical facilities.
NAMS vs SPOK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $33.9M |
| Net Profit | $-17.4M | $2.9M |
| Gross Margin | — | 76.7% |
| Operating Margin | -186.1% | 11.6% |
| Net Margin | -90.7% | 8.7% |
| Revenue YoY | 740.1% | -0.1% |
| Net Profit YoY | 55.5% | -19.6% |
| EPS (diluted) | $-0.15 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $33.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | $19.1M | $35.7M | ||
| Q1 25 | — | $36.3M | ||
| Q4 24 | $12.8M | $33.9M | ||
| Q3 24 | $29.1M | $34.9M | ||
| Q2 24 | — | $34.0M | ||
| Q1 24 | — | $34.9M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | $-17.4M | $4.6M | ||
| Q1 25 | — | $5.2M | ||
| Q4 24 | $-92.2M | $3.6M | ||
| Q3 24 | $-16.6M | $3.7M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | — | 76.7% | ||
| Q3 25 | — | 78.3% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 80.1% | ||
| Q4 24 | — | 78.5% | ||
| Q3 24 | — | 79.5% | ||
| Q2 24 | — | 78.9% | ||
| Q1 24 | — | 79.5% |
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 12.9% | ||
| Q2 25 | -186.1% | 15.1% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | -338.5% | 13.7% | ||
| Q3 24 | -85.9% | 14.2% | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | 14.0% |
| Q4 25 | — | 8.7% | ||
| Q3 25 | — | 9.5% | ||
| Q2 25 | -90.7% | 12.8% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | -721.7% | 10.8% | ||
| Q3 24 | -57.2% | 10.5% | ||
| Q2 24 | — | 10.1% | ||
| Q1 24 | — | 12.1% |
| Q4 25 | — | $0.13 | ||
| Q3 25 | — | $0.15 | ||
| Q2 25 | $-0.15 | $0.22 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | $-0.91 | $0.17 | ||
| Q3 24 | $-0.18 | $0.18 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $25.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $146.4M |
| Total Assets | $815.1M | $206.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | $739.2M | $20.2M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | $834.2M | $29.1M | ||
| Q3 24 | $422.7M | $27.8M | ||
| Q2 24 | — | $23.9M | ||
| Q1 24 | — | $23.3M |
| Q4 25 | — | $146.4M | ||
| Q3 25 | — | $148.7M | ||
| Q2 25 | $778.5M | $150.9M | ||
| Q1 25 | — | $151.7M | ||
| Q4 24 | $757.5M | $154.7M | ||
| Q3 24 | $378.9M | $156.3M | ||
| Q2 24 | — | $158.2M | ||
| Q1 24 | — | $160.2M |
| Q4 25 | — | $206.1M | ||
| Q3 25 | — | $209.7M | ||
| Q2 25 | $815.1M | $208.7M | ||
| Q1 25 | — | $204.5M | ||
| Q4 24 | $864.6M | $217.1M | ||
| Q3 24 | $439.2M | $216.8M | ||
| Q2 24 | — | $216.4M | ||
| Q1 24 | — | $215.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $11.5M |
| Free Cash FlowOCF − Capex | $-37.8M | $10.1M |
| FCF MarginFCF / Revenue | -197.2% | 29.9% |
| Capex IntensityCapex / Revenue | 0.5% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.93× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $25.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | $-37.7M | $7.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $-37.5M | $8.4M | ||
| Q3 24 | $-12.5M | $11.1M | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-37.8M | $6.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | $-37.5M | $7.5M | ||
| Q3 24 | $-12.6M | $10.3M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | 29.9% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | -197.2% | 16.8% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | -293.5% | 22.3% | ||
| Q3 24 | -43.2% | 29.4% | ||
| Q2 24 | — | 20.0% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.5% | 2.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 2.5% |
| Q4 25 | — | 3.93× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 3.03× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 0.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
SPOK
| Paging | $16.8M | 50% |
| Software Operations | $16.0M | 47% |
| License | $1.2M | 4% |
